Alliance Pharma Share Discussion Threads

[blackhorse23] 02/5/2024 10:26

Next week results day , I think will be over 70p area direction . Results will be good & loads of corporate buying will be in , push share price double from here

[baldrick1] 02/5/2024 09:09

33p likely today???

[kirmich] 01/5/2024 22:04

Quite a lot of selling and buying around 34p, i’m back in for a small position. Let’s see what the numbers bring. And the outlook. The main reason for me of buying in (aside the reasonable valuation) is that I find it difficult to believe that Dbay has this completely wrong, given their substantial position via LDG

The double postponement of the release of their yearly figures could have been handled more efficiently and creates uncertainty, hence only a small position.

[baldrick1] 01/5/2024 16:09

Rollover???

[blackhorse23] 01/5/2024 13:40

So many 100k block buying

[maverick67] 01/5/2024 12:49

32p imminent!

[wad collector] 01/5/2024 12:43

Of course you did, I believe you.

[blackhorse23] 01/5/2024 10:33

Bought more today

[baldrick1] 01/5/2024 10:09

Maybe 32p???

[baldrick1] 01/5/2024 08:23

Is this a buy @80p???

[mattboxy] 30/4/2024 20:58

Wherever you see Blackhorse push this run for the hills.

[mattboxy] 30/4/2024 20:57

Don't invest here invest in a quality company with shares that go up!

[mattboxy] 30/4/2024 20:57

Money moving out of here anywhere but here!

[blackhorse23] 30/4/2024 10:25

That's the full year results publishing next week

[wad collector] 30/4/2024 10:14

Why keep posting the old TU from January?

[maverick67] 30/4/2024 09:32

Still she on a down... moved money to card

[blackhorse23] 30/4/2024 08:46

Full Year Trading Update Strong revenues on H2 recovery, leverage reduced Alliance Pharma plc (AIM: APH), the international healthcare group, announces its trading update for the year ended 31 December 2023 (the "Period"), ahead of the announcement of the Group's audited results in March 2024, which are anticipated to be in line with market expectations.Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations.

[fatfish] 30/4/2024 08:13

still going down

[blackhorse23] 29/4/2024 16:43

1 million block buy very end of trading

[blackhorse23] 29/4/2024 16:21

AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEND +5% -PORTFOLIO BROADENED THROUGH ACQUISITION

[blackhorse23] 29/4/2024 14:51

115k block buying 4 times , something brewing

[blackhorse23] 29/4/2024 13:43

Buying this as much as possible before next week results

[baldrick1] 29/4/2024 11:14

Hey blackhorse are you trading this ???

[baldrick1] 29/4/2024 10:50

Could we buy this at 33p???